“The higher the cost of drugs,
the more the health plan has to pay toward those drugs, [and] ultimately it
goes back to the member in increasing those premiums.”
— Jamie
Miller, Geisinger Health System’s director of managed care pharmacy, spoke with
AIS’s RADAR on Drug Benefits about how payers are affected by price
fluctuations of common medications, such as insulin, and Eli Lilly’s decision
to cut its insulin prices in half.
No comments:
Post a Comment